MAPT and Alzheimer disease: Furthermore, because clinical criteria for Alzheimer’s disease have limited sensitivity and specificity for Alzheimer’s disease pathology,9 the addition of plasma-based biomarkers of phosphorylated tau to clinical workups may provide information to physicians evaluating individuals with age-related cognitive impairment.10